Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Design Example: Traverse Angle Computations01:25

Design Example: Traverse Angle Computations

341
Traverse angle computations are a critical component of surveying, used to compute the internal angles within a closed traverse. A traverse consists of a series of connected lines forming a closed loop, often used for land boundary delineation or mapping. Calculating the internal angles ensures accuracy in the traverse geometry and is essential for checking survey data integrity.The process begins with known azimuths and bearings of the traverse sides. Internal angles at each vertex are...
341
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Peptide Bonds02:43

Peptide Bonds

83.0K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

979
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
979

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Junction opener enables CAR T cell treatment of solid tumors.

Scientific reports·2026
Same author

Human epidermis models demonstrate mediator role of TLR2 and TLR3 for psoriatic inflammation.

Frontiers in medicine·2025
Same author

A standardizable human-based psoriasis skin model for drug development.

Frontiers in medicine·2025
Same author

Automation of customizable library preparation for next-generation sequencing into an open microfluidic platform.

Scientific reports·2024
Same author

Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis.

Diagnostics (Basel, Switzerland)·2023
Same author

Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.

Journal of controlled release : official journal of the Controlled Release Society·2023

Related Experiment Video

Updated: Feb 3, 2026

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.6K

Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity.

Amit Michaeli1, Shaul Mezan1, Andreas Kühbacher2

  • 1Pepticom Ltd., Givat-Ram, 9139002 Jerusalem, Israel.

Journal of Immunology (Baltimore, Md. : 1950)
|October 24, 2018
PubMed
Summary

Computational design yielded novel peptide activators for Toll-like receptor 4 (TLR4), offering alternatives to LPS-derived molecules for immune modulation and adjuvant therapies.

More Related Videos

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.6K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Related Experiment Videos

Last Updated: Feb 3, 2026

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.6K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.6K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Area of Science:

  • Immunology
  • Computational Biology
  • Drug Discovery

Background:

  • Toll-like receptor 4 (TLR4) is crucial for immune responses.
  • Current TLR4 activators are mostly lipopolysaccharide (LPS) derivatives.
  • Novel TLR4 activators are needed for immunomodulation and adjuvant applications.

Purpose of the Study:

  • To discover and optimize novel peptide activators of human TLR4.
  • To explore computational design for identifying TLR4 ligands with unique structures.
  • To develop potential alternatives to LPS-derived TLR4 agonists.

Main Methods:

  • Computational design of 53 cyclic and linear peptides targeting TLR4 coreceptors (MD2 and CD14).
  • Assessment of peptide activity using NF-κB reporter cell lines.
  • Confirmation and quantification of binding to CD14 and MD2 via MicroScale Thermophoresis.
  • Evaluation of cytokine induction in human whole blood, alone and with LPS.

Main Results:

  • Successful identification of novel peptide activators for TLR4.
  • Demonstration of computational design's efficacy in discovering structurally distinct TLR4 ligands.
  • Validation of peptide-induced cytokine production in human whole blood.
  • Peptides showed potential as standalone or synergistic immune modulators.

Conclusions:

  • Computational design is an effective strategy for discovering novel TLR4 peptide activators.
  • These peptides offer potential as easy-to-produce alternatives to LPS-derived molecules.
  • The findings support the development of new immunomodulators and adjuvants targeting TLR4.